

Press Release

Malmö, SWEDEN – October 12, 2007

Hansa Medical approved for trading on First North

Hansa Medical's application to initiate trading of the company's share on First North has been approved by OMX and, as scheduled, the first day of trading will occur on Wednesday, October 17, 2007. The Hansa Medical share will be traded under the ticker symbol HMED, with one trading unit comprising 500 shares. Hansa Medical's certified adviser is Kaupthing Bank.

Hansa Medical's CEO, Emanuel Björne:

"October 17, 2007 is an important day for Hansa Medical. We are now a fully independent, publicly traded development company with a marketplace for our shareholders. A listing on First North is well suited to Hansa Medical's needs and potential."

In September and October, Hansa Medical successfully implemented a new share issue comprising 3.8 million shares at an issue price of SEK 10, which was targeted at the general public. The issue, which generated considerable interest, was fully subscribed and enabled Hansa Medical to raise SEK 38 M before issue expenses. The proceeds of the issue will be used to finance a clinical development plan for Hansa Medical's lead project, IdeS, and key investments in two smaller projects.

Through the new share issue, Hansa Medical was spun off from its former owner, Biolin AB (publ), and the number of shares increased from 100,000 to 3,924,714. Following the issue, Hansa Medical's Chairman of the Board, Bo Håkansson, owns 36 percent of the shares in Hansa Medical through a holding company. Hansa Medical Board members Stina Gestrelus and Per Belfrage, CEO Emanuel Björne, Project Manager Anita Tocaj and research partner Professor Lars Björck also subscribed for shares in the new share issue.

About First North

First North is an alternative marketplace for small growth companies that provides visibility and ease of access to northern Europe's capital market. First North is part of the OMX Nordic Exchange Stockholm.

For more information, please contact:

Emanuel Björne, CEO

Telephone: +46 40 630 76 04

Mobile: +46 707 17 54 77

E-mail: emanuel.bjorne@hansamedical.com

ABOUT HANSA MEDICAL

Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company's long-term goal is to bring new products to market through collaboration agreements with pharmaceutical and diagnostics companies. Hansa Medical's lead project, IdeS, is an innovative drug for treatment in conjunction with organ transplantation and autoimmune disease. The company also pursues other development projects, including diagnostics and drugs for sepsis.

Hansa Medical AB
CRC Entrance 72
UMAS
SE-205 02 Malmö, Sweden
TELEPHONE +46 40 630 76 04
FAX +46 40 23 93 10

info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Clinical Research Centre at
Malmö University Hospital
Entrance 72
Malmö, Sweden